Effects of HQK-1001 in Patients With Sickle Cell Disease
Recruiting in Palo Alto (17 mi)
+17 other locations
Age: < 65
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: HemaQuest Pharmaceuticals Inc.
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The purpose of this study is to evaluate the effects of HQK-1001 on Hb F in subjects with sickle cell disease.
Research Team
RG
Richard Ghalie, MD, MBA
Principal Investigator
HemaQuest Pharmaceuticals Inc.
Eligibility Criteria
Inclusion Criteria
Males and females between 12 and 60 years of age
Diagnosis of SCD, type Hb SS or Hb S-B0 Thalassemia
At least 1 episode of SCD pain crisis, acute chest syndrome, other acute SCD complications, or leg ulcers in the 12 months prior to screening
See 7 more
Treatment Details
Interventions
- HQK-1001 (Other)
- Placebo (Drug)
Participant Groups
2Treatment groups
Active Control
Placebo Group
Group I: HQK-1001Active Control1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
The Children's Hospital at Montefiore Medical CenterBronx, NY
University of North Carolina at Chapel HillChapel Hill, NC
University of Illinois at ChicagoChicago, IL
Georgia Health Sciences UniversityAugusta, GA
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
HemaQuest Pharmaceuticals Inc.
Lead Sponsor
Trials
9
Patients Recruited
270+